XIAFLEX® CORD II Study Published In The Journal Of Hand Surgery
Links shared publicly online about this topic.
- 670total visits
XIAFLEX® CORD II Study Published In The Journal Of Hand Surgery
View full resource at medicalnewstoday.com
Tags: Surgery
Most Recently Shared on December 9, 2010 at 4:05 am By:
XIAFLEX® CORD II Study Published In The Journal Of Hand Surgery http://mnt.to/3NLn #clinicaltrials
Also Shared By:
Dupuytren's Contracture Treatment, Risk Factors, Causes, Symptoms - MedicineNet
medicinenet.com — “Read about Dupuytren's contracture treatment options: Xiaflex injection, needle aponeurotomy, ultrasound, and cortisone injection. Learn causes, risk factors, and symptoms.” View full resource at medicinenet.com
Most Recently Shared on March 8, 2012 at 6:49 pm By:
What are risk factors for a Dupuytren's contracture? http://t.co/c35LB0hf
Auxilium reports positive data from XIAFLEX retrospective commercial patient chart review
news-medical.net — “Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that positive data from a retrospective commercial patient chart review of XIAFLEX (collagenase clostridium histolyticum) used for the treatment of adult Dupuytren's contracture patients with a palpable cord are available via e-posters at the American Society for Surgery of the Hand meeting in Las Vegas.” View full resource at news-medical.net
Most Recently Shared on September 8, 2011 at 1:52 pm By:
Auxilium reports positive data from XIAFLEX retrospective commercial patient chart review: Auxilium Pharma... http://t.co/przKrLZ
Auxilium Pharmaceuticals, Inc. Announces Positive Top-Line Results from XIAFLEX Multi-Cord Study - Drugs.com MedNews
drugs.com — “Safety Profile Consistent with Clinical Trials Auxilium Pharmaceuticals, Inc. (NASDAQ AUXL), a specialty biopharmaceutical company, today announced positive top” View full resource at drugs.com
Most Recently Shared on September 7, 2011 at 7:15 pm By:
Drugs and Devices OW OW Health
Auxilium Pharmaceuticals, Inc. Announces Positive Top-Line Results from XIAFLEX Multi-Cord Study: Safety P... http://t.co/OlN0kJo #drug
Top-line results from Auxilium XIAFLEX palpable cord study in Dupuytren's contracture subjects
news-medical.net — “Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from a pilot clinical study to assess safety, tolerability, and multiple-dose pharmacokinetics of XIAFLEX (collagenase clostridium histolyticum) in adult Dupuytren's contracture subjects with multiple palpable cords.” View full resource at news-medical.net
Most Recently Shared on September 7, 2011 at 1:03 pm By:
Top-line results from Auxilium XIAFLEX palpable cord study in Dupuytren's contracture subjects: Auxilium Pharmac... http://t.co/yPwWthU
Auxilium, BioSpecifics Technologies to invest in cellulite indication for Xiaflex - Medical Marketing and Media
mmm-online.com — “Auxilium Pharmaceuticals has announced plans to invest in an indication for prescription drug Xiaflex (collagenase clostridium histolyticum), which was approved by FDA in February 2010 for adult Dupuytren's contracture patients with a palpable cord, for the treatment of cellulite.” View full resource at mmm-online.com
Most Recently Shared on September 2, 2011 at 1:44 am By:
Wendy Blackburn Health Executive
A drug for cellulite? Sign me up! :-) http://t.co/1InsWfM #pharma
Auxilium, BioSpecifics Technologies to invest in cellulite indication for Xiaflex - Medical Marketing and Media
mmm-online.com — “Auxilium Pharmaceuticals has announced plans to invest in an indication for prescription drug Xiaflex (collagenase clostridium histolyticum), which was approved by FDA in February 2010 for adult Dupuytren's contracture patients with a palpable cord, for the treatment of cellulite.” View full resource at mmm-online.com
Most Recently Shared on September 1, 2011 at 8:02 pm By:
Auxilium, BioSpecifics Technologies to invest in cellulite indication for Xiaflex: Auxilium Pharmaceut... http://t.co/w6SBkR8 from MM&M
Auxilium reports three year data from XIAFLEX CORDLESS study in Dupuytren's contracture
news-medical.net — “Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced three year recurrence data from the Collagenase Optimal Reduction of Dupuytren's - Long-term Evaluation of Success Study (CORDLESS) for XIAFLEX® (collagenase clostridium histolyticum) in the treatment of adult Dupuytren's contracture patients with a palpable cord.” View full resource at news-medical.net
Most Recently Shared on June 30, 2011 at 12:57 pm By:
Auxilium reports three year data from XIAFLEX CORDLESS study in Dupuytren's contracture: Auxilium Pharmaceutical... http://bit.ly/m1Xn0c
Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture - Drugs.com MedNews
drugs.com — “- Nominal Recurrence Rate of 34.8 at Three Years for Joints Previously Treated Successfully with XIAFLEX -93 of joints that were successfully treated with XIAFL” View full resource at drugs.com
Most Recently Shared on June 30, 2011 at 12:17 pm By:
Drugs and Devices OW OW Health
Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contrac... http://bit.ly/k0qSW2 #drug
Auxilium completes patient enrollment in XIAFLEX phase III trial against Peyronie's disease
news-medical.net — “Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced it has reached the target enrollment for the double-blind placebo-controlled phase III program of XIAFLEX for the treatment of Peyronie's disease.” View full resource at news-medical.net
Most Recently Shared on March 10, 2011 at 5:38 am By:
Prostate Cancer: Auxilium completes patient enrollment in XIAFLEX phase III trial against Peyronie's disease: Au... http://bit.ly/fqegLv
Phase 3 Study of Xiaflex for Peyronie's Disease - MPR
empr.com — “Auxilium announced completion of enrollment for its Phase 3 double-blind, placebo-controlled study of Xiaflex (collagenase clostridium histolyticum) for the treatment of Peyronie's Disease.” View full resource at empr.com
Most Recently Shared on March 9, 2011 at 5:48 pm By:
MPR News: Phase 3 Study of Xiaflex for Peyronie's Disease: Auxilium announced completion of enrollment for its P... http://bit.ly/dYvHHm
XIAFLEX® Effective In Nonsurgically Treating MP And PIP Joints With Dupuytren's Contractures In Second Pivotal Study
medicalnewstoday.com — “Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, announced that The Journal of Hand Surgery (JHS) has published in its December online edition the Company's p” View full resource at medicalnewstoday.com
Most Recently Shared on December 7, 2010 at 4:05 pm By:
MNT Bones/Orthopedic Health News
XIAFLEX® Effective In Nonsurgically Treating MP And PIP Joints With Dupuytren's Contractures In Second Pivotal Study http://mnt.to/3NG4
XIAFLEX Effective in Nonsurgically Treating MP and PIP Joints with Dupuytren's Contractures in Second Pivotal Study - Drugs.com MedNews
drugs.com — “XIAFLEX CORD II Study Published in The Journal of Hand Surgery MALVERN, Pa., Dec. 6, 2010 PRNewswire-FirstCall Auxilium Pharmaceuticals, Inc. (Nasdaq AUXL), a s” View full resource at drugs.com
Most Recently Shared on December 6, 2010 at 2:07 pm By:
Drugs and Devices OW OW Health
XIAFLEX Effective in Nonsurgically Treating MP and PIP Joints with Dupuytren's Contractures in Second Pivo... http://bit.ly/grf0RZ #drug
BioSpecifics Technologies Corp. Announces Initiation Of Global Phase 3 Trial Of XIAFLEX® For Treatment Of Peyronie's Disease
medicalnewstoday.com — “BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, announced that its partner Auxilium Pharmaceuticals, Inc. (Auxili” View full resource at medicalnewstoday.com
Most Recently Shared on October 13, 2010 at 1:05 pm By:
BioSpecifics Technologies Corp. Announces Initiation Of Global Phase 3 Trial Of XIAFLEX® For Treatment Of Peyronie... http://mnt.to/3L7g
BioSpecifics' partner Auxilium provides update on XIAFLEX
news-medical.net — “BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that its strategic partner Auxilium Pharmaceuticals, Inc. has provided an update on XIAFLEX, its injectable collagenase product currently marketed in the U.S. for the treatment of Dupuytren's contracture.” View full resource at news-medical.net
Most Recently Shared on July 13, 2010 at 4:40 am By:
BioSpecifics' partner Auxilium provides update on XIAFLEX: BioSpecifics Technologies Corp., a biopharmaceutical co... http://bit.ly/bX3VKh
Advertisement
Debby Verville
@vervilledeb1
XIAFLEX® CORD II Study Published In The Journal Of Hand Surgery http://t.co/0ZE6Mdp via @mnt_bones
1 year ago...